Figure 2From: Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary reportThe changes in the levels of fasting plasma glucose (a), HbA1c (b), fasting plasma insulin (c), HOMA-R (d) and HOMA-β (e) after the treatment with glimepiride. *p < 0.05, **p < 0.01 versus before treatment. HbA1c = hemoglobin A1c, HOMA = homeostasis model assessment.Back to article page